PHARMACY

Award in Wyeth case cut by $100 million, at least for now

BY Drew Buono

RENO, Nev. The jury in the case between Wyeth and three Nevada women who claim Wyeth’s drug Prempro and Premarin caused their breast cancer, changed the amount it awarded to the women by almost $100 million, according to the Associated Press.

The jury had originally awarded the women a combined $134.5 million, but the judge discovered that the jury might have mistakenly awarded punitive damages in the settlement. The judge was informed by the bailiff, who overheard the discussion in the jury room.

The jury will reconvene on Monday to consider awarding punitive damages. The judgment, $35 million, remains the largest award to date against Wyeth.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Wyeth hit with $134.5 million in Nevada lawsuit

BY Drew Buono

RENO, Nev. Wyeth has been ordered by a Washoe county court to pay more than $43 million each to three northern Nevada women who claimed that the company’s hormone replacement drugs, Prempro and Premarin caused their breast cancer, according to the Reno Gazette-Journal.

The jury said the drugs were defective and found the company negligent for producing, manufacturing and selling them. The jurors awarded $7.5 million to each woman in past damages and $36 million-$40 million in future damages.

The jurors still have to decide whether the company is liable for punitive damages. Wyeth is also fighting about 5,300 similar lawsuits involving 7,800 women in state and federal courts across the country.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Teva sues Apotex over Coreg infringement

BY Drew Buono

TRENTON, N.J. Teva has sued Apotex to prevent it from selling a generic version of the heart medication Coreg, according to Bloomberg.

The two companies, as well as other generic drug makers, received approval from the Food and Drug Administration to sell a generic version on Sept. 5.  Teva says it owns four patents that cover various forms and processes to make the generic, carvedilol. The company also said that Apotex might have to buy the compound made using the patented process in order to sell the generic.

The lawsuit was filed yesterday in a federal court in New Jersey. Coreg had sales of $853.8 million in the first six months of 2007.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES